Company Overview
| Stock Name | Lepu Bio |
|---|---|
| Stock Code | 02157 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 一家聚焦於腫瘤治療領域的生物製藥企業,已構建多個腫瘤產品管線,包括八種臨床階段候選藥物、三種臨床前候選藥物及三種臨床階段的候選藥物的聯合療法。候選藥物涵蓋靶向療法(包括ADC)及免疫治療(包括PD-1/PD-L1抗體及溶瘤病毒)等。 |
| Listing Date | 2022-02-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 上海市閔行區蘇召路1628號1幢C280室 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | lepubiopharma.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 7.13 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 7,130 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2022-02-10 to 2022-02-15 |
| Global Offering Shares | 126,876,000 shares |
| HK Public Offer Shares (Initial) | 12,688,000 shares (10.0%) |
| Public Offer Lots (Initial) | 12,688lots (Pool A6,344lots,Pool B6,344lots) |
| International Placing Shares (Initial) | 114,188,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,658,545,838 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 43.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 904,625,880 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 7,130 |
| 2 lots | 2,000 | HK$ 14,260 |
| 3 lots | 3,000 | HK$ 21,390 |
| 4 lots | 4,000 | HK$ 28,520 |
| 5 lots | 5,000 | HK$ 35,650 |
| 6 lots | 6,000 | HK$ 42,780 |
| 7 lots | 7,000 | HK$ 49,910 |
| 8 lots | 8,000 | HK$ 57,040 |
| 9 lots | 9,000 | HK$ 64,170 |
| 10 lots | 10,000 | HK$ 71,300 |
| 15 lots | 15,000 | HK$ 106,950 |
| 20 lots | 20,000 | HK$ 142,600 |
| 25 lots | 25,000 | HK$ 178,250 |
| 30 lots | 30,000 | HK$ 213,900 |
| 35 lots | 35,000 | HK$ 249,550 |
| 40 lots | 40,000 | HK$ 285,200 |
| 45 lots | 45,000 | HK$ 320,850 |
| 50 lots | 50,000 | HK$ 356,500 |
| 60 lots | 60,000 | HK$ 427,800 |
| 70 lots | 70,000 | HK$ 499,100 |
| 80 lots | 80,000 | HK$ 570,400 |
| 90 lots | 90,000 | HK$ 641,700 |
| 100 lots | 100,000 | HK$ 713,000 |
| 200 lots | 200,000 | HK$ 1,426,000 |
| 300 lots | 300,000 | HK$ 2,139,000 |
| 400 lots | 400,000 | HK$ 2,852,000 |
| 500 lots | 500,000 | HK$ 3,565,000 |
| 600 lots | 600,000 | HK$ 4,278,000 |
| 700 lots | 700,000 | HK$ 4,991,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 900 lots | 900,000 | HK$ 6,417,000 |
| 1,000 lots | 1,000,000 | HK$ 7,130,000 |
| 3,000 lots | 3,000,000 | HK$ 21,390,000 |
| 4,000 lots | 4,000,000 | HK$ 28,520,000 |
| 5,000 lots | 5,000,000 | HK$ 35,650,000 |
| 6,344 lots | 6,344,000 | HK$ 45,232,720 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 7.59B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 11,825,431,824 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 11,438,498,389 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 經營虧損人民幣520.4百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Balance Sheet
| Item | 2019 | 2020 | 2021-08 |
|---|---|---|---|
| Cash and cash equivalents | 188,545 | 402,867 | 261,194 |
| Inventories | 8,082 | 19,569 | 24,164 |
| Total current assets | 221,539 | 843,349 | 550,795 |
| Total assets | 1,525,281 | 2,423,611 | 2,207,026 |
| Total current liabilities | 1,215,636 | 382,221 | 278,675 |
| Total liabilities | 1,710,921 | 921,889 | 1,027,024 |
| Total equity | -185,640 | 1,501,722 | 1,180,002 |
| Equity attributable to owners | -352,500 | 1,473,511 | 1,163,609 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021-08 |
|---|---|---|---|
| Net cash from operating activities | -233,994 | -422,689 | -418,322 |
| Net cash from investing activities | -415,318 | -749,669 | -13,519 |
| Net cash from financing activities | 770,394 | 1,386,679 | 291,140 |
| Net increase in cash | 121,082 | 214,321 | -140,701 |
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 7.14 |
|---|---|
| First Day Open | HK$ 7.13 |
| First Day Change | 0.14% |
| First Day Volume | 15827000.0 |
| First Day Turnover | 112031000.0 |
| Use of Proceeds | 1、將分配約551.0百萬港元(占所得款項凈額的68.5%)為核心產品撥資;
2、將分配約51.0百萬港元(占所得款項凈額的6.3%)為公司的其他主要臨床階段候選藥物及公司的主要臨床前候選藥物撥資;
3、將分配約127.0百萬港元(占所得款項凈額的15.8%)用于收購有潛力的技術及資產及擴張公司的候選藥物管線;
4、將分配約75.2百萬港元(占所得款項凈額的9.4%)用作一般公司用途。
|
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (2)
Joint Bookrunners (6)
Joint Lead Managers (7)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | King Star Med LP | 155,854,670 HKD | — | 17.23% | — | 6 months | 2022-08-23 |
| 2 | Vivo Funds | 233,785,570 HKD | — | 25.84% | — | 6 months | 2022-08-23 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 蒲忠傑 | — |
| Company Secretary | 李昀軼、黎少娟 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股東蒲忠傑透過北京厚德義民、寧波厚德義民及樂普醫療持有權益,緊隨全球發售完成後(假設超額配股權未獲行使)將持有本公司股本總額約39.7%。 |
|---|




